Viking Therapeutics (VKTX) Total Liabilities (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Total Liabilities data on file, last reported at $106.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 429.64% year-over-year to $106.3 million; the trailing twelve-month figure through Mar 2026 stood at $106.3 million (up 429.64% YoY), and the FY2025 full-year result was $76.7 million, up 173.39% from the prior year.
• Total Liabilities grew to $106.3 million in Q1 2026, from $76.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $106.3 million in Q1 2026 to a low of $12.8 million in Q1 2022.
• A 5-year average of $30.0 million and a median of $23.2 million in 2022 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities slumped 40.3% in 2025 and jumped 429.64% in 2026, its largest moves.
• Tracing VKTX's Total Liabilities over 5 years: stood at $23.2 million in 2022, then fell by 13.51% to $20.1 million in 2023, then jumped by 39.72% to $28.0 million in 2024, then soared by 173.39% to $76.7 million in 2025, then soared by 38.68% to $106.3 million in 2026.
• Business Quant data shows VKTX's Total Liabilities at $106.3 million in Q1 2026, $76.7 million in Q4 2025, and $26.4 million in Q3 2025.